https://www.selleckchem.com/products/mek162.html
The study aimed to investigate the efficacy and safety outcomes in hormone-sensitive oligometastatic prostate cancer (OMPC) patients treated with docetaxel-based neoadjuvant chemohormonal therapy (NCHT) prior to radical prostatectomy (RP) compared with direct RP and standard androgen deprivation therapy (ADT) alone using propensity score match (PSM) analysis. A single-center, prospective, three-arm study was conducted with hormone-sensitive OMPC patients. Eligible patients (N=13 were divided into three groups-NCHT, RP, and standard tre
Like
Comment
Share
